J
Jan Philipp Bewersdorf
Researcher at Yale University
Publications - 113
Citations - 1327
Jan Philipp Bewersdorf is an academic researcher from Yale University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 14, co-authored 69 publications receiving 640 citations. Previous affiliations of Jan Philipp Bewersdorf include University Malaya Medical Centre & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
TL;DR: Recent advances in antibody-based therapy, immune checkpoint inhibitors, vaccines and adoptive cell- based therapy for patients with AML and MDS are reviewed.
Journal ArticleDOI
Calcium Influx through Plasma-Membrane Nanoruptures Drives Axon Degeneration in a Model of Multiple Sclerosis
Maarten E. Witte,Adrian Minh Schumacher,Christoph Mahler,Jan Philipp Bewersdorf,Jonas Lehmitz,Alexander Scheiter,Alexander Scheiter,Paula Sánchez,Philip R. Williams,Oliver Griesbeck,Ronald Naumann,Thomas Misgeld,Martin Kerschensteiner +12 more
TL;DR: In vivo calcium imaging in a multiple sclerosis model is used to show that cytoplasmic calcium levels determine the choice between axon loss and survival and identifies nanoscale ruptures of the axonal plasma membrane as the critical path of calcium entry.
Journal ArticleDOI
Epigenetic therapy combinations in acute myeloid leukemia: what are the options?:
TL;DR: The underlying pathophysiology and rationale for epigenetically-based combination therapies, current preclinical and clinical data, and the future directions of epigenetic therapy combinations in AML are discussed.
Journal ArticleDOI
Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
Jan Philipp Bewersdorf,Smith Giri,Rong Wang,Robert T. Williams,Martin S Tallman,Amer M. Zeidan,Maximilian Stahl +6 more
TL;DR: A systematic literature review and meta-analysis was performed to objectively assess overall response rates (ORR), and rates of CR/CRi for R/R-AML patients treated with venetoclax or venetClax + HMA/LDAC.
Journal ArticleDOI
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States.
Amer M. Zeidan,Rong Wang,Xiaoyi Wang,Rory M. Shallis,Nikolai A. Podoltsev,Jan Philipp Bewersdorf,Scott F. Huntington,Natalia Neparidze,Smith Giri,Steven D. Gore,Amy J. Davidoff,Xiaomei Ma +11 more
TL;DR: The majority of older AML patients did not receive the minimum of 4 cycles of HMA often needed to elicit clinical benefit, and there were no clinically meaningful differences between azacitidine- and decitabine-treated patients in their achievement of RBC TI or survival.